OTC · GBCS
Selectis Health, Inc.
$5.73$0.00 (0.0%)
Selectis Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.72% below the high.
Loading market information…
OTC · BICX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BioCorRx Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BioCorRx Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioCorRx Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 15, 2025 |
| -$0.06 |
| $134.90K |
| Q4 2024 | Mar 31, 2025 | -$0.08 | $62.34K |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.14 | -$62.34K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.73$0.00 (0.0%)
Selectis Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.72% below the high.
$0.02+$0.00 (+2.9%)
Xcelerate Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
CA$0.04-CA$0.02 (-27.27%)
Lobe Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 77.78% below the high.
CA$0.05CA$0.00 (0.0%)
PharmaCielo Ltd.’s quoted price sits in the lower half of its reported 52-week range, 69.7% below the high.
$1.94+$0.02 (+0.78%)
HealthLynked Corp.’s quoted price sits in the lower half of its reported 52-week range, 70.15% below the high.
$0.01+$0.01 (+733.33%)
Gnomestar Craft Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.04$0.00 (0.0%)
Veltex Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.5% below the high.
$0.09$0.00 (0.0%)
BioVaxys Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.73% below the high.
